CooperbergMR, LubeckDP, MengMV et al.. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol2004;22:2141–2149.
CooperbergMRLubeckDPMengMV. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141–2149.
)| false
LeeSJLindquistKSegalMRCovinskyKE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801–808.
)| false
D'AmicoAV, WhittingtonR, MalkowiczSB et al.. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer2002;95:281–286.
D'AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286.
)| false
James Buchanan Brady Urological Institute. Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed January 5, 2010.
James Buchanan Brady Urological Institute. Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed January 5, 2010.
)| false
MakarovDV, TrockBJ, HumphreysEB et al.. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology2007;69:1095–1101.
MakarovDVTrockBJHumphreysEB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095–1101.
)| false
KattanMW, EasthamJA, WheelerTM et al.. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003;170:1792–1797.
KattanMWEasthamJAWheelerTM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792–1797.
)| false
Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed January 5, 2010.
)| false
StephensonAJ, ScardinoPT, EasthamJA et al.. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006;98:715–717.
StephensonAJScardinoPTEasthamJA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–717.
)| false
StephensonAJ, KattanMW, EasthamJA et al.. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol2009;27:4300–4305.
GraefenM, HaeseA, PichlmeierU et al.. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol2001;165:857–863.
GraefenMHaeseAPichlmeierU. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857–863.
)| false
OhoriM, KattanMW, KohH et al.. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol2004;171:1844–1849; discussion 1849.
OhoriMKattanMWKohH. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844–1849; discussion 1849.
)| false
SteuberT, GraefenM, HaeseA et al.. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol2006;175:939–944; discussion 944.
SteuberTGraefenMHaeseA. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939–944; discussion 944.
)| false
BrigantiA, ChunFK, SaloniaA et al.. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol2007;51:112–119; discussion 119–120.
BrigantiAChunFKSaloniaA. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007;51:112–119; discussion 119–120.
)| false
KattanMW, PottersL, BlaskoJC et al.. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology2001;58:393–399.
KattanMWPottersLBlaskoJC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393–399.
)| false
PottersL, MorgensternC, CalugaruE et al.. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol2008;179:S20–24.
JeldresC, SuardiN, WalzJ et al.. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol2008;54:1306–1313.
JeldresCSuardiNWalzJ. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306–1313.
)| false
StephensonAJ, ScardinoPT, KattanMW et al.. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol2007;25:2035–2041.
StephensonAJScardinoPTKattanMW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–2041.
)| false
DearnaleyDP, KhooVS, NormanAR et al.. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet1999;353:267–272.
DearnaleyDPKhooVSNormanAR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267–272.
)| false
D'AmicoAV, CoteK, LoffredoM et al.. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol2002;20:4567–4573.
D'AmicoAV, ChenMH, RoehlKA, CatalonaWJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004;351:125–135.
D'AmicoAVChenMHRoehlKACatalonaWJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125–135.
)| false
D'AmicoAV, MoulJW, CarrollPR et al.. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003;95:1376–1383.
D'AmicoAVMoulJWCarrollPR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–1383.
)| false
SakrWA, GrignonDJ, CrissmanJD et al.. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo1994;8:439–443.
SakrWAGrignonDJCrissmanJD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439–443.
)| false
ThompsonIM, PaulerDK, GoodmanPJ et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med2004;350:2239–2246.
ThompsonIMPaulerDKGoodmanPJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239–2246.
)| false
DraismaG, EtzioniR, TsodikovA et al.. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst2009;101:374–383.
DraismaGEtzioniRTsodikovA. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–383.
)| false
BastianPJMangoldLAEpsteinJIPartinAW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004;101:2001–2005.
)| false
ChunFK, HaeseA, AhyaiSA et al.. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer2008;113:701–709.
ChunFKHaeseAAhyaiSA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701–709.
)| false
BastianPJ, CarterBH, BjartellA et al.. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol2009;55:1321–1330.
BastianPJCarterBHBjartellA. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321–1330.
)| false
DraismaG, BoerR, OttoSJ et al.. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst2003;95:868–878.
DraismaGBoerROttoSJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–878.
)| false
ShappleyWVIII, KenfieldSA, KasperzykJL et al.. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol2009;27:4980–4985.
ShappleyWVIIIKenfieldSAKasperzykJL. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980–4985.
)| false
Bill-AxelsonA, HolmbergL, FilenF et al.. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst2008;100:1144–1154.
Bill-AxelsonAHolmbergLFilenF. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144–1154.
)| false
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol1997;79:235–246.
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235–246.
)| false
CarterHB, KettermannA, WarlickC et al.. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol2007;178:2359–2364; discussion 2364–2355.
CarterHBKettermannAWarlickC. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359–2364; discussion 2364–2355.
)| false
ChooR, KlotzL, DanjouxC et al.. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol2002;167:1664–1669.
StephensonAJ, AprikianAG, SouhamiL et al.. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology2002;59:652–656.
StephensonAJAprikianAGSouhamiL. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002;59:652–656.
)| false
HanlonAL, Watkins BrunerD, PeterR, HanksGE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys2001;49:51–59.
HanlonALWatkins BrunerDPeterRHanksGE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:51–59.
)| false
KoperPC, StroomJC, van PuttenWL et al.. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys1999;43:727–734.
MichalskiJM, BaeK, RoachM et al.. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys2010;76:14–22.
MichalskiJMBaeKRoachM. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010;76:14–22.
)| false
PeetersST, HeemsbergenWD, KoperPC et al.. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol2006;24:1990–1996.
PeetersSTHeemsbergenWDKoperPC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–1996.
)| false
PollackA, ZagarsGK, StarkschallG et al.. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys2002;53:1097–1105.
PollackAZagarsGKStarkschallG. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–1105.
)| false
ZietmanAL, DeSilvioML, SlaterJD et al.. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA2005;294:1233–1239.
ZietmanALDeSilvioMLSlaterJD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233–1239.
)| false
KubanDA, TuckerSL, DongL et al.. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008;70:67–74.
KubanDATuckerSLDongL. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
)| false
PotoskyAL, DavisWW, HoffmanRM et al.. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst2004;96:1358–1367.
PotoskyALDavisWWHoffmanRM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367.
)| false
D'AmicoAV, ManolaJ, LoffredoM et al.. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA2004;292:821–827.
NguyenPL, D'AmicoAV, LeeAK, SuhWW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer2007;110:1417–1428.
NguyenPLD'AmicoAVLeeAKSuhWW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417–1428.
)| false
D'AmicoAV, MoranBJ, BraccioforteMH et al.. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol2009;27:3923–3928.
D'AmicoAVMoranBJBraccioforteMH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:3923–3928.
)| false
NagS, BiceW, DeWyngaertK et al.. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys2000;46:221–230.
NagSBiceWDeWyngaertK. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221–230.
)| false
HartsellWF, ScottCB, BrunerDW et al.. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst2005;97:798–804.
HartsellWFScottCBBrunerDW. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798–804.
)| false
KonskiA, JamesJ, HartsellW et al.. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol2009;32:423–428.
KonskiAJamesJHartsellW. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol 2009;32:423–428.
)| false
JanjanN, LutzST, BedwinekJM et al.. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med2009;12:417–426.
JanjanNLutzSTBedwinekJM. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med 2009;12:417–426.
)| false
AlbertsenPC, HanleyJA, GleasonDF, BarryMJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA1998;280:975–980.
AlbertsenPCHanleyJAGleasonDFBarryMJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975–980.
)| false
AbelEJ, MastersonTA, WarnerJN et al.. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology2009;73:1336–1340.
DavisJW, ChangDW, ChevrayP et al.. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol2009;55:1135–1143.
DavisJWChangDWChevrayP. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009;55:1135–1143.
)| false
CagiannosI, KarakiewiczP, EasthamJA et al.. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol2003;170:1798–1803.
MastersonTA, BiancoFJJr, VickersAJ et al.. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol2006;175:1320–1324; discussion 1324–1325.
MastersonTABiancoFJJrVickersAJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320–1324; discussion 1324–1325.
)| false
AllafME, PalapattuGS, TrockBJ et al.. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol2004;172:1840–1844.
AllafMEPalapattuGSTrockBJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840–1844.
)| false
BaderP, BurkhardFC, MarkwalderR, StuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?J Urol2003;169:849–854.
BaderPBurkhardFCMarkwalderRStuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?J Urol 2003;169:849–854.
)| false
DaneshmandS, QuekML, SteinJP et al.. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol2004;172:2252–2255.
DaneshmandSQuekMLSteinJP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252–2255.
)| false
LabrieF, DupontA, BelangerA, LachanceR. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol1987;138:804–806.
LabrieFDupontABelangerALachanceR. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138:804–806.
)| false
SchulzeH, SengeT. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol1990;144:934–941.
SchulzeHSengeT. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990;144:934–941.
)| false
IversenP, JohanssonJE, LoddingP et al.. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol2006;40:441–452
IversenPJohanssonJELoddingP. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40:441–452)| false
BollaM, ColletteL, BlankL et al.. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet2002;360:103–106.
BollaMColletteLBlankL. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–106.
)| false
ShelleyMD, KumarS, WiltT et al.. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev2009;35:9–17.
ShelleyMDKumarSWiltT. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17.
)| false
BollaM, GonzalezD, WardeP et al.. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997;337:295–300.
BollaMGonzalezDWardeP. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
)| false
DenhamJW, SteiglerA, LambDS et al.. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol2005;6:841–850.
LoblawDA, VirgoKS, NamR et al.. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2007;25:1596–1605.
LoblawDAVirgoKSNamR. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–1605.
)| false
MessingEM, ManolaJ, YaoJ et al.. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol2006;7:472–479.
MessingEMManolaJYaoJ. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–479.
)| false
McLeodDG, SeeWA, KlimbergI et al.. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol2006;176:75–80.
McLeodDGSeeWAKlimbergI. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006;176:75–80.
)| false
Lu-YaoGL, AlbertsenPC, MooreDF et al.. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA2008;300:173–181.
Lu-YaoGLAlbertsenPCMooreDF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181.
)| false
SmithMR, LeeWC, BrandmanJ et al.. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol2005;23:7897–7903.
SmithMRLeeWCBrandmanJ. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–7903.
)| false
DiamondT, CampbellJ, BryantC, LynchW. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer1998;83:1561–1566.
DiamondTCampbellJBryantCLynchW. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561–1566.
)| false
MaillefertJF, SibiliaJ, MichelF et al.. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol1999;161:1219–1222.
MaillefertJFSibiliaJMichelF. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–1222.
)| false
SmithMR, McGovernFJ, ZietmanAL et al.. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med2001;345:948–955.
SmithMRMcGovernFJZietmanAL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–955.
)| false
SmithMR, FinkelsteinJS, McGovernFJ et al.. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab2002;87:599–603.
SmithMRFinkelsteinJSMcGovernFJ. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599–603.
)| false
DiamondTH, WintersJ, SmithA et al.. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer2001;92:1444–1450.
DiamondTHWintersJSmithA. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444–1450.
)| false
SmithMR, EasthamJ, GleasonDM et al.. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003;169:2008–2012.
SmithMREasthamJGleasonDM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.
)| false
MichaelsonMD, KaufmanDS, LeeH et al.. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol2007;25:1038–1042.
MichaelsonMDKaufmanDSLeeH. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038–1042.
)| false
GreenspanSL, NelsonJB, TrumpDL, ResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med2007;146:416–424.
GreenspanSLNelsonJBTrumpDLResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416–424.
)| false
SmithMR, MalkowiczSB, ChuF et al.. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol2008;179:152–155.
SmithMRMalkowiczSBChuF. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152–155.
)| false
SmithMR, MalkowiczSB, ChuF et al.. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol2008;26:1824–1829.
SmithMRMalkowiczSBChuF. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008;26:1824–1829.
)| false
SaigalCS, GoreJL, KrupskiTL et al.. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer2007;110:1493–1500.
SaigalCSGoreJLKrupskiTL. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493–1500.
)| false
D'AmicoAV, DenhamJW, CrookJ et al.. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol2007;25:2420–2425.
D'AmicoAVDenhamJWCrookJ. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420–2425.
)| false
StuderUE, WhelanP, AlbrechtW et al.. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol2006;24:1868–1876.
StuderUEWhelanPAlbrechtW. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 2006;24:1868–1876.
)| false
TsaiHK, D'AmicoAV, SadetskyN et al.. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst2007;99:1516–1524.
TsaiHKD'AmicoAVSadetskyN. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516–1524.
)| false
BerrutiA, DogliottiL, TerroneC et al.. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol2002;167:2361–2367; discussion 2367.
BerrutiADogliottiLTerroneC. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361–2367; discussion 2367.
)| false
TayekJA, HeberD, ByerleyLO et al.. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism1990;39:1314–1319.
DockeryF, BulpittCJ, AgarwalS et al.. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond)2003;104:195–201.
DockeryFBulpittCJAgarwalS. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195–201.
)| false
SmithJC, BennettS, EvansLM et al.. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab2001;86:4261–4267.
SmithJCBennettSEvansLM. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261–4267.
)| false
EriLM, UrdalP, BechensteenAG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol1995;154:100–104.
EriLMUrdalPBechensteenAG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995;154:100–104.
)| false
College of American Pathologists. Cancer Protocols and Checklists: Prostate Gland. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2006/prostate06_pw.pdf. Accessed January 5, 2010.
College of American Pathologists. Cancer Protocols and Checklists: Prostate Gland. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2006/prostate06_pw.pdf. Accessed January 5, 2010.
)| false
WolfJSJr, CherM, Dall'eraM et al.. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol1995;153:993–999.
WolfJSJrCherMDall'eraM. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153:993–999.
)| false
JohanssonJE, HolmbergL, JohanssonS et al.. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA1997;277:467–471.
JohanssonJEHolmbergLJohanssonS. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467–471.
)| false
D'AmicoAV, ChenMH, RenshawAA et al.. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA2008;299:289–295.
D'AmicoAVChenMHRenshawAA. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–295.
)| false
WidmarkA, KleppO, SolbergA et al.. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet2009;373:301–308.
WidmarkAKleppOSolbergA. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–308.
)| false
HorwitzEM, BaeK, HanksGE et al.. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol2008;26:2497–2504.
HorwitzEMBaeKHanksGE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497–2504.
)| false
ThompsonIM, TangenCM, ParadeloJ et al.. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol2009;181:956–962.
ThompsonIMTangenCMParadeloJ. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956–962.
)| false
SwansonGP, GoldmanB, TangenCM et al.. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol2008;180:2453–2457; discussion 2458.
SwansonGPGoldmanBTangenCM. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol 2008;180:2453–2457; discussion 2458.
)| false
Van der KwastTH, BollaM, Van PoppelH et al.. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol2007;25:4178–4186.
Van der KwastTHBollaMVan PoppelH. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:4178–4186.
)| false
WiegelT, BottkeD, SteinerU et al.. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol2009;27:2924–2930.
WiegelTBottkeDSteinerU. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924–2930.
)| false
CheungR, KamatAM, de CrevoisierR et al.. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys2005;63:134–140.
CheungRKamatAMde CrevoisierR. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005;63:134–140.
)| false
LeeAK, D'AmicoAV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol2005;23:8192–8197.
LeeAKD'AmicoAV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005;23:8192–8197.
)| false
PatelR, LeporH, ThielRP, TanejaSS. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology2005;65:942–946.
PatelRLeporHThielRPTanejaSS. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology 2005;65:942–946.
)| false
WardJF, ZinckeH, BergstralhEJ et al.. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol2004;172:2244–2248.
WardJFZinckeHBergstralhEJ. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:2244–2248.
)| false
TrockBJ, HanM, FreedlandSJ et al.. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA2008;299:2760–2769.
TrockBJHanMFreedlandSJ. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760–2769.
)| false
CherML, BiancoFJJr, LamJS et al.. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol1998;160:1387–1391.
CherMLBiancoFJJrLamJS. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387–1391.
)| false
RoachMIII, HanksG, ThamesHJr et al.. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys2006;65:965–974.
RoachMIIIHanksGThamesHJr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–974.
)| false
IsmailM, AhmedS, KastnerC, DaviesJ. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int2007;100:760–764.
IsmailMAhmedSKastnerCDaviesJ. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100:760–764.
)| false
AllenGW, HowardAR, JarrardDF, RitterMA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer2007;110:1405–1416.
AllenGWHowardARJarrardDFRitterMA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 2007;110:1405–1416.
)| false
PucarD, Shukla-DaveA, HricakH et al.. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology2005;236:545–553.
WestphalenAC, KurhanewiczJ, CunhaRM et al.. T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol2009;35:171–180; discussion 181–172.
WestphalenACKurhanewiczJCunhaRM. T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol 2009;35:171–180; discussion 181–172.
)| false
DupontA, GomezJL, CusanL et al.. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol1993;150:908–913.
DupontAGomezJLCusanL. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908–913.
)| false
SartorAO, TangenCM, HussainMH et al.. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer2008;112:2393–2400.
SartorAOTangenCMHussainMH. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393–2400.
)| false
SmallEJ, HalabiS, DawsonNA et al.. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol2004;22:1025–1033.
SmallEJHalabiSDawsonNA. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025–1033.
)| false
PetrylakDP, TangenCM, HussainMH et al.. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med2004;351:1513–1520.
PetrylakDPTangenCMHussainMH. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–1520.
)| false
TannockIF, de WitR, BerryWR et al.. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med2004;351:1502–1512.
TannockIFde WitRBerryWR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.
)| false
BertholdDR, PondGR, SobanF et al.. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol2008;26:242–245.
BertholdDRPondGRSobanF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–245.
)| false
MachielsJP, MazzeoF, ClausseM et al.. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol2008;26:5261–5268.
MachielsJPMazzeoFClausseM. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26:5261–5268.
)| false
KantoffPW, SchuetzT, BlumensteinBA. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract 5013.
KantoffPWSchuetzTBlumensteinBA. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 5013.
)| false
SchellbammerPF, HiganoC, BergerER et al.. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract]. Presented at the American Urological Association Annual Meeting 2009. April 25–30, 2009; Chicago, Illinois. Late-breaking Abstract 9.
SchellbammerPFHiganoCBergerER. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract]. Presented at the American Urological Association Annual Meeting 2009. April 25–30, 2009; Chicago, Illinois. Late-breaking Abstract 9.
)| false
SaadF, GleasonDM, MurrayR et al.. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst2002;94:1458–1468.
SaadFGleasonDMMurrayR. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–1468.
)| false
SaadF, GleasonDM, MurrayR et al.. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst2004;96:879–882.
SaadFGleasonDMMurrayR. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879–882.
)| false
MarxRE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg2003;61:1115–1117.